Solvonis Therapeutics (LON: SVNS) shares surged 13% in early trading after the company announced positive preclinical pharmacokinetic data for its lead Alcohol Use Disorder treatment candidate, SVN-002, marking an important
Traders Cafe with Zak Mir: Bulletin Board Heroes, Monday 20th April 2026
Zak Mir takes a charting look at some of the most closely followed small caps on the London Stock Exchange. Today’s charts are for the FTSE 100, DAX, Dow, Bitcoin, Ethereum,
Solvonis Therapeutics plc (LON: SVNS) Logo SVN-015 accepted into US NIDA funded programme
Solvonis’ Novel Compound SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction